AbbVie has announced the European Commission (EC) has granted marketing authorization for ELAHERE (mirvetuximab soravtansine) ...

AbbVie receives European marketing approval for Elahere for the treatment of platinum-resistant ovarian cancer: North Chicago, Illinois Tuesday, November 19, 2024, 10:00 Hrs [IST] ...

NEW YORK – The European Commission (EC) on Monday granted marketing authorization to AbbVie's Elahere (mirvetuximab soravtansine) as a new therapy option for previously treated patients with folate ...

Roche (RHHBY) announced that it has received CE Mark for its Ventana FOLR1 RxDx Assay. This is the first immunohistochemistry, or IHC, ...

Swiss drug major Roche Group (RHHBY) announced Monday that it has received CE Mark for its VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, ...

AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha ...

The US FDA has approved Vyloy in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of advanced gastric or gastroesophageal junction cancer.

Source: ELRIG (UK) Ltd. Flow cytometry competition binding is a relatively novel characterization assay designed to enable epitope binning using the competitive binding profiles of monoclonal ...

Cell viabilities were monitored daily using acridine orange / propidium iodide (AO/PI) stain and its respective dual fluorescent assay. Preliminary results showed that viabilities for all SupT1 ...

This adds value to multiplex assays, proving to be a positive market force. Key Findings from the Market Report The global multiplex assay market is segmented based on product type, the technology ...

This study highlights the clinical utility of the PredicineCARE™ liquid biopsy assay in Roche’s pivotal INAVO120 Phase 3 clinical trial of Inavolisib (Itovebi), which targets patients with ...